Company intelligence / Profile preview
ThirtyFiveBio Limited
Milton (near Oxford), England, United Kingdom30fivebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ThirtyFiveBio has developed multiple unique families of first-in-class small-molecule GPR35 inhibitors. The lead program(s) are in preclinical development, including IND-enabling studies to support the initiation of first-in-human clinical trials. Preclinical data presented at AACR validated GPR35 as a novel cancer target and described potent, selective inhibitors. No clinical results reported yet.
- Therapeutic areas
- Gastroenterology
- Modalities
- small molecules (specifically small molecule antagonists/inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
AbbVie Ventures – strategic investment/collaboration on IBD pipeline substrate potential
Beyond the preview
Go deeper on ThirtyFiveBio Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ThirtyFiveBio Limited.